Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of “Hold” from Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has earned a consensus recommendation of “Hold” from the three research firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $28.00.

Separately, StockNews.com raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, April 5th.

Hedge Funds Weigh In On Atara Biotherapeutics

Several hedge funds have recently modified their holdings of the stock. Josh Arnold Investment Consultant LLC boosted its position in Atara Biotherapeutics by 17.6% during the third quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 30,000 shares during the last quarter. Private Advisor Group LLC boosted its holdings in shares of Atara Biotherapeutics by 53.0% in the 3rd quarter. Private Advisor Group LLC now owns 95,463 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 33,063 shares during the last quarter. Vontobel Holding Ltd. bought a new position in shares of Atara Biotherapeutics in the fourth quarter valued at $41,000. SG Americas Securities LLC bought a new stake in Atara Biotherapeutics during the third quarter worth $57,000. Finally, Redmile Group LLC lifted its stake in Atara Biotherapeutics by 3.8% in the third quarter. Redmile Group LLC now owns 6,280,813 shares of the biotechnology company’s stock valued at $9,296,000 after acquiring an additional 232,690 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Trading Down 6.0 %

ATRA opened at $0.63 on Thursday. The stock has a market capitalization of $75.84 million, a P/E ratio of -0.24 and a beta of 0.70. Atara Biotherapeutics has a 12 month low of $0.20 and a 12 month high of $3.02. The firm’s fifty day simple moving average is $0.70 and its 200 day simple moving average is $0.73.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.05. The company had revenue of $4.25 million for the quarter, compared to analyst estimates of $2.45 million. Atara Biotherapeutics had a negative return on equity of 783.31% and a negative net margin of 3,220.88%. On average, equities research analysts predict that Atara Biotherapeutics will post -1.3 EPS for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.